期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 15, 期 -, 页码 461-477出版社
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/3630
关键词
Diabetes mellitus; Mesenchymal stem cells; adult stem cells; insulin producing cells; induced pluripotent stem cells; human embryonic stem cells; nuclear reprogramming; MicroRNAs; stem cell therapy; pancreas development; beta-cells regeneration; Review
资金
- NIH [HL-71010, HL-74185, HL-88012, NS-51568]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088012, R01HL074185, R01HL071010] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051568] Funding Source: NIH RePORTER
The rapidly increasing number of diabetes patients across the world poses a great challenge to the current therapeutic approach. The traditional method of exogenous supply of insulin has ephemeral effect and often causes lethal hypoglycemia that demands to develop a novel strategy. Recent investigations on regeneration of insulin producing cells (IPCs) revealed that in addition to primary source i.e., pancreatic beta cells, IPCs can be derived from several alternative sources including embryonic, adult, mesenchymal and hematopoietic stem cells via the process of proliferation, dedifferentiation, neogenesis, nuclear reprogramming and transdifferentiation. There is considerable success in insulin independency of diabetes patient after transplantation of whole pancreas and / or the islet cells. However, the major challenge for regenerative therapy is to obtain a large source of islet / beta cells donor. Recent advances in the directed differentiation of stem cells generated a promising hope for a better and permanent insulin independency for diabetes. In this review we discussed stem cells as a potential future therapeutic target for the treatment of diabetes and associated diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据